Imprese · 29/10/20261 min di lettura
iOnctura to present late-breaking data on roginolisib in immunotherapy-resistant NSCLC at SITC
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
Data from the ongoing PULMO-01 clinical study to be presented on November 6, 2026, at SITC 2026 Roginolisib is the first conformation-selective PI3Kδ inhibitor that locks the enzyme in its inactive state CAMBRIDGE,…